abstract: BACKGROUND AND OBJECTIVE: A @entity3809 ( @entity3809 ) is a type of @entity1462 composed of malformed, dilated blood vessels within the papillary and @entity2363 . Currently, pulsed dye laser (PDL) is considered the therapeutic gold standard, although greater than 90% of lesions may be refractory to treatment. Studies have shown that a delay in treatment results in a higher proportion of @entity1 who develop @entity1184 and nodularity within lesions that become more resistant to therapy. Therapeutic resistance is multifactorial, but is believed to be largely due to revascularization after laser treatment. Oral @entity3446 and topical imiquimod have shown promise as adjunctive therapies to minimize post-laser revascularization, but both have significant side effects. We wish to demonstrate the utility of adjunct topical @entity3446 to reduce revascularization after PDL treatment. STUDY DESIGN/ @entity1 AND METHODS: This is a single @entity1 case report of a 56-year-old male @entity1 with an extensive @entity3809 . After seeing initial improvement with PDL alone, he began to experience thickening and nodularity of his @entity3809 necessitating surgical debulking. Since this procedure, topical @entity3446 0.5% ointment has been added to his treatment regimen as an adjunct to PDL. The @entity1 is being treated with PDL (Vbeam Perfecta, Candela/Syneron, Wayland, MA) every 4-6 weeks at varied settings with the following laser parameters: fluence 9-11   J/cm(2) , pulse duration 0.45-1.5   ms, focal spot size 7   mm, cooling 30/20. @entity3446 0.5% ointment is applied to the area twice daily. RESULTS: The @entity1 showed significant improvement in color and texture of his @entity3809 . Compared to the initial therapy of PDL alone, topical @entity3446 ointment in conjunction with PDL demonstrated greater improvement and maintenance of therapeutic results with fewer overall laser treatments. CONCLUSION: Topical @entity3446 0.5% ointment is a safe and effective adjunct to PDL in the treatment of @entity3809 . Lasers Surg. Med. 48:193-196, 2016.    2015 Wiley Periodicals, Inc.

title: Port wine stain treated with a combination of pulsed dye laser and topical XXXX ointment.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus', 'Sirolimus']

entities_list: @entity3809 :: ('MESH:D019339', 'Disease') :: ['PWS', 'port wine stain']

entities_list: @entity2363 :: ('MESH:C538361', 'Disease') :: ['reticular dermis']

entities_list: @entity1462 :: ('MESH:D054079', 'Disease') :: ['capillary vascular malformation']

answer: @entity3446 :: (MESH:D020123,Chemical) :: ['rapamycin']


abstract: Platelet production, distribution, and destruction have been quantitated in normal @entity1 and in selected @entity1 with @entity1423 . In most instances, total production as calculated from the megakaryocyte mass agreed with production estimated from platelet turnover. In @entity1 with megaloblastosis, a discrepancy between these two measurements indicated the presence of ineffective thrombopoiesis. Thrombopoiesis was regulated by (a) alterations in megakaryocyte number, and (b) changes in megakaryocyte volume (produced by changes in endomitosis). The volume-endomitosis changes were closely related to the peripheral platelet count and were a useful indicator of thrombopoietic stimulus. @entity882 have been classified on the basis of the disturbed physiology into disorders of (a) production (hypoproliferative or ineffective), (b) distribution (splenic pooling), or (c) destruction (immune or consumptive). Less than a twofold increase in platelet production in the presence of significant @entity882 was taken to represent impaired proliferation. @entity1148 was classified as reactive or autonomous. Reactive @entity1148 was consistently associated with a mean megakaryocyte volume and endomitosis less than normal but appropriate for the elevated circulating platelet count. In contrast, the average megakaryocyte volume and nuclear number were always greater than normal in @entity1148 findings indicating autonomy.

title: Thrombokinetics in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocythemia', 'Thrombocytosis', 'thrombocytosis']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['Thrombocytopenic disorders', 'thrombocytopenia']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet disorders']

answer: @entity1 :: (9606,Species) :: ['man']


abstract: There have been no reports on the relationship of subgingival temperature to specific gingival crevicular fluid (GCF) components. Therefore, the purpose of this cross-sectional study was to determine whether there was any relationship between subgingival temperature and GCF levels of neutrophil elastase (NE), @entity3335 ( @entity3335 ), beta-glucuronidase (BG), @entity1192 ( @entity1192 ), and interferon alpha (IFN). Furthermore, another objective was to confirm an association of subgingival temperature with clinical parameters and specific @entity527 micro-organisms as has been reported earlier. 27 @entity1 subjects each having healthy (n = 50), @entity2522 (n = 59) and @entity2521 (n = 53) sites were evaluated. The plaque index (PI), subgingival temperature, probing depth, @entity6730 , @entity548 index and gingival index were measured. GCF was sampled following the measurement of the PI and removal of the @entity527 . GCF samples were assayed for the enzymes NE, BG, @entity3335 and the cytokines @entity3027 and @entity1192 . A sterile Gracey curette was utilized at each sampled site to collect @entity527 . The plaque samples were evaluated using an immunoassay. Subgingival temperature was found to directly correlate with all clinical parameters (p < 0.001). Significant, albeit not large, correlations were found between subgingival temperature and NE (r = 0.35, p < 0.001), @entity3335 (r = 0.26, p < 0.001) and BG (r = 0.23, p < 0.01). Temperature was found to correlate positively with @entity4424 (r = 0.33, p < 0.02) and @entity8209 (r = 0.25, p < 0.05) but not with @entity3288 (r = 0.02, p = 0.9), @entity2523 (r = 0.20, p = 0.1) and A. actinomycetemcomitans (r = 0.01, p > 0.9). In conclusion, subgingival temperature is correlated with the GCF enzymes, NE, @entity3335 and BG as well as the clinical parameters and specific plaque micro-organisms associated with @entity2520 .

title: Subgingival temperature: relation to gingival crevicular fluid enzymes, cytokines, and XXXX micro-organisms.

entities_list: @entity6730 :: ('MESH:D017622', 'Disease') :: ['attachment loss']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['subgingival plaque', 'supragingival plaque']

entities_list: @entity3335 :: ('4353', 'Gene') :: ['MPO', 'myeloperoxidase']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity2520 :: ('MESH:D010510', 'Disease') :: ['periodontal disease']

entities_list: @entity2522 :: ('MESH:D005891', 'Disease') :: ['gingivitis']

entities_list: @entity2521 :: ('MESH:D010518', 'Disease') :: ['periodontitis']

entities_list: @entity2523 :: ('837', 'Species') :: ['P. gingivalis']

answer: @entity527 :: (MESH:D058225,Disease) :: ['subgingival plaque']


abstract: Traditionally, immunosuppressive maintenance therapy in solid organ transplantation has consisted of @entity205 ( @entity870 ), @entity500 , and @entity229 . However, lung transplant recipients are far more frequently affected by acute rejection, especially during the first 6 months after the transplantation, than @entity1 with other transplanted organs. Further, they display a greater risk for chronic @entity8 and ultimate graft loss. @entity4154 ( @entity4154 ) is the major cause of morbidity and mortality among long-term survivors after lung transplantation. Acute pulmonary allograft rejection has been identified as the major risk factor for the development of @entity4154 . Based on favourable results in kidney, liver, and heart transplantation, @entity1140 and @entity618 have been used as primary prophylaxis and as rescue therapy for recurrent or persistent acute rejection and @entity4154 . A secondary indication is CsA @entity137 . This review focuses on reported results of the combination of @entity1140 and @entity618 in lung transplantation. These new immunosuppressive drugs have markedly improved the efficacy profiles without additional detrimental @entity137 , and appear to be a safe alternative to CsA and @entity500 in @entity1 following lung transplantation. However, at present, @entity4154 is not influenced by these new drugs. The optimal long-term immunosuppressive regimen remains to be established.

title: Lung transplants with @entity1140 and XXXX : a review.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['transplant dysfunction']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']

entities_list: @entity4154 :: ('MESH:D001989', 'Disease') :: ['Bronchiolitis obliterans syndrome', 'BOS']

answer: @entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']


abstract: UNASSIGNED: @entity69151 , an @entity69152 , was isolated from Salvia austriaca transformed roots grown in in vitro conditions. The compound is known to have antibacterial, cytotoxic and anti- @entity5 properties. This study evaluates the ability of pure @entity69151 and extracts obtained from the S. austriaca hairy roots and roots from field-grown plants to inhibit @entity1 acetylcholinesterase and butyrylcholinesterase. Both extracts were found to have similar actions against acetylcholinesterase. The IC50 for extracts from transformed and untransformed roots were 142.5 and 139.5     g   @entity4654 , respectively. The highest activity towards @entity1 acetylcholinesterase was demonstrated by @entity69151 (IC50    =   54.84     g   @entity4654 ). With respect to @entity1390 inhibition, the root extracts demonstrated stronger activity (IC50    =   23.6     g   @entity4654 : field-grown plants and 41.6     g   @entity4654 : transformed roots) than @entity69151 (IC50    =   195.9     g   @entity4654 ). @entity69151 showed significant cytotoxicity against A549 cell line (IC50    =   9.1     g   @entity4654 ), whereas the activities for the extracts from S. austriaca roots of field-grown plants (IC50    =   75.7     g   @entity4654 ) and hairy roots (IC50    =   86.2     g   @entity4654 ) were lower. Computer modelling suggests that @entity69151 should not demonstrate @entity1370 or genotoxic activity. It also indicates that @entity69151 should demonstrate very rapid transport from the body with very good blood-brain barrier penetration, but with no cumulative effect on the @entity1 body. The obtained results indicate that @entity69151 is a safe compound and may be used for further investigations in pharmacological activities. Copyright    2015 John Wiley _ Sons, Ltd.

title: @entity69151 and Extracts from Salvia austriaca Roots as XXXX Cholinesterase Inhibitors.

entities_list: @entity69152 :: ('CHEBI:36762', 'Chemical') :: ['abietane diterpenoid']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity69151 :: ('MESH:C009387', 'Chemical') :: ['taxodione', 'Taxodione']

entities_list: @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiotoxic']

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: PURPOSE/OBJECTIVES: To describe and understand the perceptions of @entity146 ( @entity146 ) and the interests and preferences for a @entity146 intervention of @entity1 on @entity342 -deprivation therapy (ADT) within a two-phase (formative and intervention research) feasibility study.   . RESEARCH APPROACH: Qualitative, descriptive.   . SETTING: Princess Margaret Cancer Centre and Odette Cancer Centre, both in Toronto, Ontario, Canada.   . @entity1 : 27 @entity1 on ADT.   . METHODOLOGIC APPROACH: @entity1 were recruited from @entity263 clinics. Nine focus groups were conducted from November 2013 to April 2014 until data saturation was reached. Probe questions assessed perceptions regarding @entity146 and preferences for a mobile @entity146 intervention. Data were transcribed verbatim, and a thematic analysis was conducted.   . FINDINGS: Twenty-seven @entity1 with a mean age of 73.5 years (SD = 8.1 years) volunteered for the study. Most @entity1 were aware of the health risks associated with @entity146 , but most discussed @entity146 in terms of increasing physical activity (PA). Many @entity1 were interested in a mobile application to reduce @entity146 and expressed that the design should be easy to use, have an alerting function to interrupt sitting, have the ability to track and monitor PA levels, be tailored to the individual, and involve social support.    . CONCLUSIONS: These findings will inform the development and evaluation of a novel @entity146 intervention to improve health outcomes in this population.   . INTERPRETATION: Oncology nurses may serve as a motivational factor in encouraging @entity1 on ADT to reduce @entity146 .    .

title: A Qualitative Study Exploring the Perceptions    of Sedentary Behavior in XXXX Survivors Receiving @entity342 -Deprivation Therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Men', 'PARTICIPANTS', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['sedentary behavior', 'SED']

answer: @entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']


abstract: @entity604 is an inevitable result of getting older in both sexes. This loss is accelerated in @entity1 in the early years following menopause and in both sexes with drugs and diseases, prominently @entity1378 . @entity170 and @entity1378 , both of which are widely recognized clinical entities, have been thought to arise from low @entity172 levels and high thyroid hormone levels, respectively. However, when @entity172 declines, follicle-stimulating hormone, an anterior pituitary hormone, rises. Likewise, when thyroid hormone levels rise in @entity1378 , thyroid-stimulating hormone levels fall. We have used a complement of @entity19 genetic, pharmacological, and cell biological approaches to unravel a direct action of follicle-stimulating hormone and thyroid-stimulating hormone on bone remodeling and bone mass. Apart from establishing a novel pituitary-bone axis of physiological significance, our studies challenge the existing 1-hormone, 1-disease paradigm in endocrinology and suggest that a plurality of hormonal disturbances involving pituitary hormones cause postmenopausal and @entity1378 . New therapeutic targets thus emerge from these studies. Mt Sinai J Med 76:474-483, 2009. (c) 2009 Mount Sinai School of Medicine.

title: Paradigm shift in the pathophysiology of postmenopausal and XXXX .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity604 :: ('MESH:D016301', 'Disease') :: ['Bone loss']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['Postmenopausal osteoporosis']

entities_list: @entity1378 :: ('MESH:D006980', 'Disease') :: ['hyperthyroid osteoporosis', 'hyperthyroidism', 'hyperthyroid osteoporoses']

answer: @entity170 :: (MESH:D010024,Disease) :: ['thyrotoxic osteoporosis']


abstract: CONTEXT: @entity4854 in hospitalized @entity1 is associated with increased morbidity and mortality. OBJECTIVE: We examined whether @entity3124 is more strongly associated with relative or @entity4854 . DESIGN: The study was an observational cohort study. @entity1 AND SETTING: A total of 2290 @entity1 acutely admitted to a tertiary hospital. MAIN OUTCOME MEASURE: The relative @entity4854 ( @entity4854 ratio [SHR]) was defined as admission @entity413 divided by estimated average @entity413 derived from glycosylated hemoglobin. The relationships between @entity413 and SHR with @entity3124 (in-hospital death or critical care) were examined. RESULTS: In univariable analyses, SHR (odds ratio, 1.23 per 0.1 increment [95% confidence interval, 1.18-1.28]; P < .001) and @entity413 (odds ratio, 1.18 per mmol/L [1.13-1.23]; P < .001) were associated with @entity3124 . In multivariable analysis, the association was maintained for SHR (odds ratio, 1.20 per 0.1 increment [1.13-1.28]; P < .001), but not @entity413 (odds ratio, 1.03 per mmol/L [0.97-1.11]; P = .31). Background @entity4854 affected the relationship between @entity413 (P = .002) and @entity3124 , but not SHR (P = .35) and @entity3124 . In @entity1 with admission @entity413  <=10 mmol/L, the odds ratio for @entity3124 was higher in the fourth (2.4 [1.4-4.2]; P = .001) and fifth (3.9 [2.3-6.8]; P < .001) SHR quintiles than in the lowest SHR quintile. CONCLUSIONS: SHR controls for background glycemia and is a better biomarker of @entity3124 than @entity4854 . SHR identifies @entity1 with relative @entity4854 at risk of @entity3124 . Future studies should explore whether basing @entity413 -lowering therapy on relative, rather than absolute, @entity4854 improves outcomes in hospitalized @entity1 .

title: Relative @entity4854 , a Marker of @entity3124 : Introducing the Stress XXXX Ratio.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity3124 :: ('MESH:D016638', 'Disease') :: ['critical illness']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia', 'stress hyperglycemia', 'Hyperglycemia', 'absolute hyperglycemia']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity4854 :: (MESH:D006943,Disease) :: ['Hyperglycemia']


abstract: Adjuvants Systems (AS) containing immunostimulant combinations are used in @entity1 vaccines. Safety pharmacology studies evaluated the cardiorespiratory effects of AS in conscious telemetered @entity235 and in anaesthetised @entity35 . Sixteen telemetered @entity235 (4/group) received intramuscular injections of saline at Day 0, and one clinical dose of AS01, AS03, AS04 or AS15 at Day 7 (7  the equivalent @entity1 dose on a bodyweight basis). Bodyweights were measured through Day 14 and cardiorespiratory parameters and body temperature through 72 h post-treatment. Anaesthetised @entity35 (4/group) received one intravenous injection of AS01, AS03 or AS15 at 1 mL/kg bodyweight (140  the equivalent @entity1 dosages), or saline. Cardiorespiratory parameters were measured for 120 min post-dose. In @entity235 , food consumption and mean bodyweight decreased with AS03, and mean body temperature slightly increased with AS01, AS03 and AS15, but were not considered to be adverse. Cardiovascular effects (a slight, reversible increase in mean heart rate and shortened mean RR/PR/QT-intervals) were observed with AS15. No relevant clinical effects or effects on QRS-complex/QTc-interval durations, arterial pressure or respiratory parameters were observed. In @entity35 , there were no consistent treatment-related effects. Collectively, this suggests that AS01, AS03, AS04 and AS15 are not associated with potentially deleterious effects on ventricular repolarisation, atrio/intra-ventricular conductivities or respiratory functions.

title: Effects of Adjuvant Systems on the cardiovascular and respiratory functions in telemetered conscious XXXX and anaesthetised @entity35 .

entities_list: @entity235 :: ('9615', 'Species') :: ['dogs', 'beagle dogs']

answer: @entity235 :: (9615,Species) :: ['dogs']


abstract: Clinical studies have shown that probiotics positively affect oral health by decreasing gum bleeding and/or reducing salivary counts of certain oral pathogens. Our aim was to investigate the inhibitory effect of six probiotic lactobacilli against opportunistic @entity6923 species. Sugar utilisation by both lactobacilli and Candida was also assessed. Agar overlay assay was utilised to study growth inhibition of @entity5132 , @entity7408 and Candida krusei by @entity1905 , @entity3869 @entity6329 Shirota, @entity68352 , @entity3869 CD2, @entity6330 LB86 and @entity6330 LB Lact. The inhibitory effect was measured at pH 5.5, 6.4, and 7.2, respectively, and in the presence of five different @entity3363 in growth medium ( @entity413 , @entity948 , @entity1132 , @entity969 , and @entity5121 ). Growth and final pH values were measured at two-hour time points to 24 h. @entity1905 showed the strongest inhibitory activity in @entity948 and @entity413 medium against @entity5132 , followed by @entity6329 Shirota, @entity68352 and @entity3869 CD2. None of the lactobacilli tested affected the growth of C. krusei. Only @entity1905 produced slight inhibitory effect on @entity7408 . The lower pH values led to larger inhibition zones. Sugar fermentation profiles varied between the strains. @entity6329 Shirota grew in the presence of all @entity3363 tested, whereas @entity3869 CD2 could utilise only @entity413 and @entity948 . All Candida species metabolised the available @entity3363 but the most rapid growth was observed with @entity7408 . The results suggest that commercially available probiotics differ in their inhibitory activity and @entity1735 utilisation; the above properties are modified by different pH values and @entity3363 with more pronounced inhibition at lower pH.

title: Inhibitory activity in vitro of probiotic lactobacilli against XXXX under different fermentation conditions.

entities_list: @entity6923 :: ('MESH:C536777', 'Disease') :: ['oral Candida']

entities_list: @entity7408 :: ('5478', 'Species') :: ['C. glabrata', 'Candida glabrata']

entities_list: @entity948 :: ('MESH:D005632', 'Chemical') :: ['fructose']

entities_list: @entity5121 :: ('MESH:D013012', 'Chemical') :: ['sorbitol']

entities_list: @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate']

entities_list: @entity5132 :: ('5476', 'Species') :: ['C. albicans', 'Candida albicans']

entities_list: @entity3869 :: ('1580', 'Species') :: ['Lactobacillus', 'L. brevis', 'Lactobacillus brevis']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

entities_list: @entity6330 :: ('1585', 'Species') :: ['Lactobacillus bulgaricus', 'L. bulgaricus']

entities_list: @entity68352 :: ('491077', 'Species') :: ['L. reuteri SD2112', 'Lactobacillus reuteri SD2112']

entities_list: @entity1905 :: ('568703', 'Species') :: ['L. rhamnosus GG', 'Lactobacillus rhamnosus GG']

entities_list: @entity3363 :: ('MESH:D002241', 'Chemical') :: ['carbohydrates', 'sugars']

answer: @entity6923 :: (MESH:C536777,Disease) :: ['oral Candida']


abstract: In a population-based case-control study we have previously shown that 14% of healthy Manitobans carry one or two mutations in the @entity6820 locus, a gene highly associated with @entity30 ( @entity30 ). The @entity6820 protein is the receptor responsible for recognition of bacterial peptidoglycans, and it is plausible that @entity6820 is involved in the recognition of mycobacteria. Thirty-seven percent of Manitobans with @entity30 had >or=1 @entity6820 mutation, leading to a threefold increased risk of @entity30 for single-mutant carriers and a 30-fold increased risk for double-mutant carriers. In the same population groups, we assessed the seroprevalence for Mycobacterium @entity3068 and found it to be 35%, with no differences between @entity30 , @entity31 ( @entity31 ), and controls. Because of high rates of @entity30 and @entity31 in Manitoba, we assessed whether there was an interaction between carrying a @entity6820 mutation and M. @entity3068 seropositivity. An enzyme-linked immunosorbent assay for serum antibodies to M. @entity3068 in @entity291 was adapted for @entity1 use. DNA was purified from whole blood. Subjects were genotyped for three @entity6820 variants, @entity20717 , @entity69880 , and @entity20716 . Multivariate logistic regression analysis showed that @entity6820 gene mutations significantly associated with @entity30 , but M. @entity3068 serology did not. Furthermore, there was no interaction between @entity6820 mutation status and M. @entity3068 serology status. For those with the @entity6820 mutation, the likelihood of @entity30 subjects having positive M. @entity3068 serology was similar to that of controls (odds ratio, 1.31; 95% confidence interval, 0.55-3.11). No interaction could be proven for @entity31 or by combining @entity30 and @entity31 compared to controls. In conclusion, we could not find an interaction between the @entity6820 genotype and M. @entity3068 serology in relationship to @entity30 or @entity31 .

title: Testing the interaction between @entity6820 status and serological response to Mycobacterium XXXX in cases of inflammatory bowel disease.

entities_list: @entity69880 :: ('c|INS|1007|C', 'ProteinMutation') :: ['Cins1007fs']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]

entities_list: @entity3068 :: ('MESH:D010283', 'Disease') :: ['paratuberculosis']

answer: @entity3068 :: (MESH:D010283,Disease) :: ['paratuberculosis']


abstract: PURPOSE: The value of specialization has frequently been challenged by many health care institutions and providers. This review was conducted to determine whether there were any outcome differences in the management of @entity292 complicating @entity4436 . METHODS: We conducted an historical cohort study using hospital charts of all cases of @entity292 complicating @entity4436 that were operated on in four university-affiliated hospitals between 1975 and 1995. There were 122 @entity1 , with 37 under the care of fully trained colorectal surgeons and 85 under the care of general surgeons. RESULTS: There were no significant differences in @entity1 demographics, preoperative comorbidities, or the number of preoperative diagnostic investigations between the two groups. The colorectal surgeons performed more intraoperative ureteral stenting (Colorectal Surgery 55.5 percent vs. General Surgery 24.4 percent, P = 0.001). The general surgeons performed more initial diverting Hartmann's and colostomy procedures (Colorectal Surgery 5.4 percent vs. General Surgery 27 percent, P = 0.013). The @entity1 in the General Surgery group had longer preoperative lengths of stay (median Colorectal Surgery 3 (range, 1-28) days vs. General Surgery 8 (range, 0-29) days; P < 0.001), longer postoperative lengths of stay (median Colorectal Surgery 11 (range, 5-40) days vs. General Surgery 14 (range, 2-80) days; P = 0.001), and longer total lengths of stay (median Colorectal Surgery 14 (range, 6-62) days vs. General Surgery 24 (range, 6-100) days; P < 0.001). The @entity1 in the General Surgery group experienced a higher rate of wound @entity281 (Colorectal Surgery 5.4 percent vs. General Surgery 12.9 percent), and a larger proportion of them experienced complications (Colorectal Surgery 27 percent vs. General Surgery 41.2 percent). CONCLUSIONS: We conclude that specialization in colon and rectal surgery contributed to an improved outcome, with a lower rate of diverting procedures, a shorter hospital stay, and a lower rate of complications.

title: The value of specialization--is there an outcome difference in the management of @entity292 complicating XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['fistulas']

entities_list: @entity4436 :: ('MESH:D004238', 'Disease') :: ['diverticulitis']

answer: @entity4436 :: (MESH:D004238,Disease) :: ['diverticulitis']


abstract: UNASSIGNED: @entity1 value rewards less when these are delivered in the future as opposed to immediately, a phenomenon referred to as delay discounting. While delay discounting has been studied during the anticipation of rewards and in the context of intertemporal decision-making, little is known about its neural correlates in the outcome phase (during reward delivery) and their relation to @entity1314 . Personality traits that have been associated with increased delay discounting include @entity23 and, potentially, @entity308 . Here we performed functional magnetic resonance imaging (fMRI) in 72 healthy @entity1 while they carried out a @entity245 ( @entity245 ) task with a delay manipulation. In sixty percent of the experimental trials, @entity1 won rewards that differed in magnitude (0.05   , 0.50    or 1   ) and delay until delivery (immediately, 10 days, or 100 days). A factor analysis on questionnaires yielded two factors reflecting Impulsivity and @entity308 , which we used to examine potential relationships between @entity1314 and delay discounting. When winning a reward, medial prefrontal cortex (mPFC) activation was higher for immediate compared to delayed rewards. Moreover, amygdala activation correlated with reward magnitude for immediate but not for delayed rewards. Amygdala activation to winning immediate rewards was higher in more impulsive @entity1 , while mPFC activation to winning immediate rewards was higher in more anxious-depressed @entity1 . Our results uncover neural correlates of delay discounting during reward delivery, and suggest that @entity23 and subclinical @entity308 are related to stronger neural responses for winning immediate relative to delayed rewards.

title: XXXX without decision-making: medial prefrontal cortex and amygdala activations reflect immediacy processing and correlate with @entity23 and @entity308 .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Humans']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['anxious-depressive traits', 'Anxiety/Depression']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['MID', 'monetary incentive delay']

entities_list: @entity23 :: ('MESH:D007174', 'Disease') :: ['impulsivity']

entities_list: @entity1314 :: ('MESH:D010554', 'Disease') :: ['personality']

answer: @entity245 :: (MESH:D002658,Disease) :: ['Delay discounting']


abstract: BACKGROUND: @entity1 with a complication of pregnancy are at increased risk of @entity65 and mortality later in life. Yet, information on risk of recurrent events in @entity1 with a previous cardiovascular event is lacking. We aimed to assess the relationship between early @entity3152 , (recurrent) miscarriage and the risk for recurrent @entity65 in @entity1 with @entity455 . METHODS: We included 1014 @entity1 with a mean age of 60 years from the SMART study, a prospective ongoing cohort study among subjects with clinically @entity455 . The included @entity1 had a history of >= 1 pregnancy and were followed for the occurrence of subsequent vascular events. The relationship between the pregnancy complications ((miscarriage (gestational age <14 weeks), recurrent miscarriage (>= 3 miscarriages) and early @entity3152 (gestational age 14-32 weeks)) and @entity65 and mortality were estimated using multivariable adjusted hazard ratios. RESULTS: During a mean follow-up of 5.0 years, 80 @entity1 had a recurrent cardiovascular event, of which 28 were fatal. A history of recurrent miscarriage was associated with an increased risk for a recurrent cardiovascular event (hazard ratio 4.3 95% confidence interval 1.7--10.9). In addition, early @entity3152 was related to a 4.1 (95% confidence interval 1.5--11.3) fold increased risk of @entity65 in @entity1 with previous @entity65 . No statistically significant relationships were found for less than three miscarriages. CONCLUSIONS: In @entity1 with previous @entity65 , an obstetric history of recurrent miscarriage is associated with an increased risk of recurrent @entity65 and early @entity3152 with @entity65 .

title: Relationship between recurrent miscarriage and early @entity3152 and recurrent events in XXXX with @entity455 : The SMART study.

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['manifest vascular disease']

entities_list: @entity3152 :: ('MESH:D007752', 'Disease') :: ['preterm delivery']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality', 'cardiovascular death', 'cardiovascular events', 'cardiovascular disease', 'cardiovascular morbidity']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: @entity68917 , approved in late 2014 in the United States and Japan for the treatment of @entity22 characterized by difficulty achieving and/or maintaining sleep, is a dual orexin receptor antagonist and the first drug in its class to reach the market. Its development followed from the 1998 discovery of orexins (also called hypocretins), excitatory neuropeptides originating from neurons in the hypothalamus involved in regulation of sleep and wake, feeding behavior and energy regulation, motor activity, and reward-seeking behavior. @entity68917 objectively improves sleep, shortening the time to achieve persistent sleep and reducing wake after sleep onset, although at approved doses ( <=20 mg) the benefit was subjectively assessed as modest. Its half-life of 12 hours is relatively long for a modern hypnotic; however, at approved doses ( <=20 mg) next-day sedation and driving impairment were much less apparent than at higher doses. @entity68917 is metabolized by the hepatic @entity5322 system and should be avoided in combination with strong @entity5322 inhibitors. Drug levels are higher in @entity1 and @entity28 @entity1 ; hence, dosing should be conservative in @entity28 @entity1 . Administration with food delays drug absorption and is not advised. No dose adjustment is needed for advanced age, @entity8 , or mild-to-moderate @entity409 . @entity68917 in contraindicated in @entity2724 and has not been studied in @entity1 . In alignment with the changes begun in 2013 in the labeling of other hypnotics, the United States Food and Drug Administration advises that the lowest dose effective to treat symptoms be used and that @entity1 be advised of the possibility of next-day impairment in function, including driving. Infrequent but notable side effects included @entity854 , @entity2726 , and suicidal ideation that were dose-related and reported to be mild. Given its mechanism of action, @entity2725 and rapid eye movement (REM) @entity146 could potentially occur in some @entity1 taking this medication.

title: Profile of XXXX in the management of @entity22 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'children', 'patients', 'people']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment']

entities_list: @entity2725 :: ('MESH:D002385', 'Disease') :: ['cataplexy']

entities_list: @entity2726 :: ('MESH:D020188', 'Disease') :: ['sleep paralysis']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['sleep behavior disorder']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['hepatic impairment']

entities_list: @entity2724 :: ('MESH:D009290', 'Disease') :: ['narcolepsy']

entities_list: @entity68917 :: ('MESH:C551624', 'Chemical') :: ['Suvorexant']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['abnormal dreams']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']

answer: @entity68917 :: (MESH:C551624,Chemical) :: ['suvorexant']


abstract: BACKGROUND: @entity8 is a common cause of the @entity1985 . Treatment with standard regimens fails to induce complete remission in most @entity1 . We evaluated the efficacy of combination therapy with rituximab, low-dose, oral @entity786 , and an accelerated @entity229 taper ( @entity11663 ) for the treatment of @entity8 . METHODS: We analyzed 15 consecutive @entity1 with @entity8 treated with @entity11663 at Massachusetts General Hospital. Seven @entity1 (47%) received @entity11663 as initial therapy, and the other eight @entity1 (53%) received @entity11663 for relapsing or refractory disease. All @entity1 had at least 1  year of follow-up. The co-primary outcomes were attainment of partial and complete remission. Partial remission was defined as a urinary protein to @entity1011 ratio (UPCR)   <   3  g/g and a 50% reduction from baseline. Complete remission was defined as a UPCR   <   0.3  g/g. Secondary outcomes were serious adverse events and the change in @entity644 , serum @entity1011 , serum albumin, @entity165 , @entity1674 , and immunoglobulin G levels after 1  year of treatment. RESULTS: Over a median follow-up time of 37 (IQR, 34-44) months, 100% of @entity1 achieved partial remission and 93% of @entity1 achieved complete remission at a median time of 2 and 13  months, respectively. After 1  year of treatment, median (IQR) UPCR declined from 8.2 (6.6-11.1) to 0.3 (0.2-0.7) g/g (P   <   0.001). Three serious adverse events occurred over 51 @entity1 years. No @entity1 died or progressed to ESKD. CONCLUSIONS: Treatment of @entity8 with @entity11663 resulted in high rates of complete remission. Larger studies evaluating this regimen are warranted.

title: Combination therapy with rituximab, low-dose @entity786 , and XXXX for @entity8 : a case series.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['Membranous nephropathy', 'idiopathic membranous nephropathy']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity229 :: (MESH:D011241,Chemical) :: ['prednisone']


abstract: @entity161 is a life-long debilitating @entity146 affecting tens of millions of @entity1 worldwide. The serendipitous discovery of antipsychotics focused pharmaceutical research on developing a better antipsychotic. Our understanding of the disorder has advanced however, with the knowledge that @entity73 are required for @entity1 in order to improve their everyday lives. While antipsychotics treat @entity716 , they do not enhance cognition and hence are not antischizophrenics. Developing pro-cognitive therapeutics has been extremely difficult, however, especially when no approved treatment exists. In lieu of stumbling on an efficacious treatment, developing targeted compounds can be facilitated by understanding the neural mechanisms underlying altered cognitive functioning in @entity1 . Equally importantly, these cognitive domains will need to be measured similarly in animals and @entity1 so that novel targets can be tested prior to conducting expensive clinical trials. To date, the limited similarity of testing across species has resulted in a translational bottleneck. In this review, we emphasize that @entity161 is a disorder characterized by abnormal @entity73 . Quantifying these abnormalities using tasks having cross-species validity would enable the quantification of comparable processes in rodents. This approach would increase the likelihood that the neural substrates underlying relevant behaviors will be conserved across species. Hence, we detail cross-species tasks which can be used to test the effects of manipulations relevant to @entity161 and putative therapeutics. Such tasks offer the hope of providing a bridge between non-clinical and clinical testing that will eventually lead to treatments developed specifically for @entity1 with @entity73 .

title: Developing treatments for XXXX in @entity161 : the challenge of translation.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'patients', 'people']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental disorder']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive enhancers', 'deficient cognition', 'cognitive behavior']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia', 'Schizophrenia']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis']

answer: @entity73 :: (MESH:D003072,Disease) :: ['cognitive deficits']


abstract: Novel molecular photochemistry can be developed by combining high pressure and laser irradiation. For studying such high-pressure effects on the confined electronic ground and excited states, we extend the PCM (polarizable continuum model) SAC (symmetry-adapted cluster) and SAC-CI (SAC-configuration interaction) methods to the PCM-XP (extreme pressure) framework. By using the PCM-XP SAC/SAC-CI method, molecular systems in various electronic states can be confined by polarizable media in a smooth and flexible way. The PCM-XP SAC/SAC-CI method is applied to a @entity16100 ( @entity69725 ) molecule in @entity13479 at high pressure (1-60 GPa). The relationship between the calculated free-energy and cavity volume can be approximately represented with the Murnaghan equation of state. The excitation energies of @entity16100 in @entity13479 show blueshifts with increasing pressure, and the extents of the blueshifts significantly depend on the character of the excitations. Particularly large confinement effects are found in the Rydberg states. The energy ordering of the lowest Rydberg and valence states alters under high-pressure. The pressure effects on the electronic structure may be classified into two contributions: a confinement of the molecular orbital and a suppression of the mixing between the valence and Rydberg configurations. The valence or Rydberg character in an excited state is, therefore, enhanced under high pressure.

title: Modeling Molecular Systems at Extreme Pressure by an Extension of the Polarizable Continuum Model (PCM) Based on the Symmetry-Adapted Cluster-Configuration Interaction (SAC-CI) Method: Confined Electronic Excited States of XXXX as a Test Case.

entities_list: @entity13479 :: ('MESH:C506365', 'Chemical') :: ['cyclohexane']

answer: @entity16100 :: (MESH:C039281,Chemical) :: ['Furan']


abstract: Allogeneic donor T cells in bone marrow transplantation (BMT) can contribute to @entity2132 (GVL) effects but can also cause @entity2132 ( @entity2132 ). A successful method for the ex vivo treatment of donor T cells to limit their @entity2132 potential while retaining GVL activity would have broad clinical applications for @entity1 undergoing allogeneic hematopoietic cell transplantation for @entity5 . We hypothesized that donor lymphocyte infusions treated with @entity3118 , an immunosuppressive @entity2353 analog, would have reduced @entity2132 potential in a fully major histocompatibility complex-mismatched C57BL/6 --> B10.BR @entity19 BMT model. Recipients of @entity3118 -treated donor lymphocyte infusions (F-DLI) had significantly reduced @entity2132 mortality, reduced histopathologic evidence of @entity2132 , and lower inflammatory serum cytokine levels than recipients of untreated DLI. Combined comparisons of @entity2132 incidence and donor-derived hematopoietic chimerism indicated that F-DLI had a therapeutic index superior to that of untreated DLI. Furthermore, adoptive immunotherapy of @entity981 using F-DLI in the C57BL/6 --> B10.BR model demonstrated a broad therapeutic index with markedly reduced @entity2132 activity and preservation of GVL activity compared with untreated allogeneic T cells. @entity3118 exposure markedly reduced the @entity404 + @entity1759 (low)-naive donor T-cell population within 48 hours of transplantation and altered the relative representation of cytokine-producing @entity404 + T cells, consistent with T-helper type 2 polarization. However, proliferation of @entity3118 -treated T cells in allogeneic recipient spleens was equivalent to that of untreated T cells. The results suggest that @entity3118 reduces the @entity2132 potential of donor lymphocytes through effects on a @entity404 + @entity1759 (low) T-cell population, with less effect on alloreactive T cells and @entity404 + @entity1759 (high) memory T cells that are able to mediate GVL effects. Thus, F-DLI represents a novel method of immune modulation that may be useful to enhance immune reconstitution among allograft recipients with reduced risk of @entity2132 while retaining beneficial GVL effects.

title: Ex vivo XXXX exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2353 :: ('CHEBI:33838', 'Chemical') :: ['nucleoside']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['lymphoblastic lymphoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant diseases']

entities_list: @entity3118 :: ('MESH:C024352', 'Chemical') :: ['Fludarabine', 'fludarabine']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['detrimental graft-versus-host disease', 'beneficial graft-versus-leukemia', 'GVHD']

answer: @entity3118 :: (MESH:C024352,Chemical) :: ['fludarabine']


abstract: The V0V1-ATPase of @entity4691 catalyzes @entity855 synthesis coupled with proton translocation. It consists of an ATPase-active V1 part (ABDF) and a proton channel V0 part (CLEGI), but the arrangement of each subunit is still largely unknown. Here we found that acid treatment of V0V1-ATPase induced its dissociation into two subcomplexes, one with subunit composition ABDFCL and the other with EGI. Exposure of the isolated V0 to acid or 8 m @entity1133 also produced two subcomplexes, EGI and CL. Thus, the C subunit (homologue of d subunit, @entity375 @entity58890 ) associates with the L subunit ring tightly, and I (homologue of 100-kDa subunit, @entity375 @entity11858 ), E, and G subunits constitute a stable complex. Based on these observations and our recent demonstration that D, F, and L subunits rotate relative to A3B3 (Imamura, H., Nakano, M., Noji, H., Muneyuki, E., Ohkuma, S., Yoshida, M., and Yokoyama, K. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 2312-2315; Yokoyama, K., Nakano, M., Imamura, H., Yoshida, M., and Tamakoshi, M. (2003) J. Biol. Chem. 278, 24255-24258), we propose that C, D, F, and L subunits constitute the central rotor shaft and A, B, E, G, and I subunits comprise the surrounding stator apparatus in the V0V1-ATPase.

title: Subunit arrangement in V-ATPase from XXXX .

entities_list: @entity4691 :: ('274', 'Species') :: ['Thermus thermophilus']

answer: @entity4691 :: (274,Species) :: ['Thermus thermophilus']


abstract: UNASSIGNED: To evaluate the incidence of @entity5 ( @entity5 ) in @entity1 with @entity43 using a nationwide retrospective population-based dataset. @entity1 newly diagnosed with @entity43 between 1997 and 2010 were identified using Taiwan's National Health Insurance database. @entity1 with antecedent @entity5 were excluded. Standardized incidence ratios (SIRs) for @entity5 were calculated and compared with the @entity5 incidence in the general population. Risk factors for @entity5 development were analyzed using Cox proportional hazard models. Effects of surgery, chemotherapy, and radiotherapy after @entity43 diagnosis were regarded as time-dependent variables to prevent immortal time bias.During the 14-year study period (follow-up of 56,214 @entity1 -years), 707 @entity5 developed in 12,127 @entity1 with @entity43 . The SIR for all @entity5 was 2.78 (95% confidence interval 2.58-3.00). SIRs for follow-up periods of>5, 1-5, and<1 year were 1.87, 2.04, and 6.40, respectively. After the exclusion of @entity5 occurring within 1 year of @entity43 diagnosis, SIRs were significantly higher for @entity5 of the colon, rectum, and anus (2.14); lung and mediastinum (1.58); breast (1.68); cervix (1.65); uterus (7.96); bladder (3.17), and thyroid (2.23); as well as for @entity1778 (3.98) and others (3.83). Multivariate analysis showed that age >=  50 years was a significant @entity5 risk factor (hazard ratio [HR] 1.60). Different treatments for @entity43 , including radiotherapy (HR 2.07) and chemotherapy (HR 1.27), had different impacts on @entity5 risk. @entity1 with @entity43 are at increased risk of @entity5 development. Age >=  50 years, radiotherapy, and chemotherapy are independent risk factors. Close surveillance of @entity1 at high risk should be considered for the early detection of @entity5 .

title: Secondary Primary Malignancy Risk in XXXX With @entity43 in Taiwan: A Nationwide Population-Based Study.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['SPM', 'cancers', 'secondary primary malignancy', 'cancer', 'malignancies']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'person']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: BACKGROUND: @entity927 has an inhibitory action on ultraviolet (UV) B-induced melanocyte activation. This study examined the sex differences in the inhibitory action of @entity927 on UVB-induced melanocyte activation. METHODS: We irradiated the eye and ear of male and female @entity19 with UVB at a dose of 1.0 kJ/m(2) using a 20SE sunlamp. We orally administered @entity927 (750 mg/kg/day) at 30 min before UVB exposure. RESULTS: @entity927 inhibited the UVB-induced epidermal melanocyte activation, and the effect was more remarkable under UVB eye irradiation than under UVB ear irradiation. Furthermore, the melanocyte activity suppression effect was stronger in female @entity19 than in male @entity19 . Following the administration of @entity927 , the female displayed increased blood levels of b-endorphin and  -opioid receptor and @entity53 receptor b expression in comparison to the male. Furthermore, the effect of melanocyte activity suppression in the female @entity19 was decreased by the administration of @entity440 (antagonist of @entity172 receptor) or @entity836 (antagonist of  -opioid receptor). CONCLUSIONS: These results suggest that the suppression by @entity927 of the UVB-induced melanocyte activation (UVB sensitivity) is stronger in female @entity19 than in male @entity19 , and that female hormones and b-endorphin play an important role in this sex difference. This article is protected by copyright. All rights reserved.

title: The gender differences in the inhibitory action of UVB-induced melanocyte activation by the administration of XXXX .

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity836 :: ('MESH:D009271', 'Chemical') :: ['naltrexone']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']

entities_list: @entity927 :: ('MESH:D014148', 'Chemical') :: ['tranexamic acid', 'Tranexamic acid']

answer: @entity927 :: (MESH:D014148,Chemical) :: ['tranexamic acid']


abstract: BACKGROUND: This split-mouth clinical study aimed to investigate levels of @entity5843 (a2M) in gingival crevicular fluid (GCF) of @entity7278 @entity1 pre- and post-scaling and root planing (SRP) with or without adjunctive use of @entity803 fibers. MATERIALS AND METHODS: In 30 @entity1 of @entity7278 , samples of GCF were collected from the gingival sulcus before SRP. Recording of clinical parameters was conducted. This was followed by @entity734 ( @entity734 ) of @entity803 fibers in test sites. In control sites, no @entity734 was done. Second samples of GCF were taken 90 days after treatment. Samples of crevicular fluid were analyzed to determine the levels of a2m. RESULTS: A gain of clinical attachment (CAL) of 3.30 mm for SRP and @entity734 and for SRP alone was 1.62 mm (p < 0.001). The pocket probing depth was significantly decreased by 2.43 mm for SRP and @entity734 and for SRP alone was 1.61 mm (p < 0.001) after 90 days. @entity5843 was significantly reduced in GCF by SRP and SRP and @entity734 after 90 days (p < 0.001). CONCLUSION: Clinical and biochemical variables showed a more favorable outcome when SRP was combined with @entity734 of @entity803 fibers in management of @entity1 suffering from @entity7278 .

title: @entity5843 Levels in Gingival Crevicular Fluid Pre- and Post-scaling and Root Planing with Adjunctive XXXX Fibers in @entity7278 : A Randomized Controlled Trial.

entities_list: @entity5843 :: ('2', 'Gene') :: ['Alpha-2-macroglobulin', 'alpha-2-macroglobulin']

entities_list: @entity7278 :: ('MESH:D055113', 'Disease') :: ['chronic periodontitis']

entities_list: @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['local drug delivery', 'LDD']

answer: @entity803 :: (MESH:D013752,Chemical) :: ['Tetracycline']


abstract: BACKGROUND: Little is known about whether @entity955 is a presentation of @entity301 . There is a paucity of knowledge about their causal relationship and also the impact of different antithrombotic strategies on the subsequent presentation of symptomatic @entity301 . METHODS AND RESULTS: We studied 7,526 Chinese @entity1 diagnosed with non-valvular @entity955 and no documented history of @entity453 . The primary endpoint was the new occurrence of @entity453 or @entity1187 . After a mean follow-up of 3.2  3.5 years (24,071 @entity1 -years), a primary endpoint occurred in 987 @entity1 (13.1%). The overall annual incidence of @entity453 was 4.10%/year. No significant differences in age, sex, and mean CHA2DS2-VASc score were observed between @entity1 with and without the primary endpoint. When stratified according to the antithrombotic strategies applied for @entity64 prevention, the annual incidence of @entity453 was 5.49%/year, 4.45%/year and 2.16%/year respectively in those prescribed no antithrombotic therapy, @entity117 , and @entity1229 . Similar trends were observed in @entity1 with @entity1187 . @entity6 , smoking history and @entity177 requiring dialysis were predictors for primary endpoint in all antithrombotic therapies. CONCLUSION: In @entity1 with non-valvular @entity955 , there is a modest association with @entity453 . @entity1 prescribed @entity1229 had the lowest risk of new onset @entity453 .

title: Impact of Antithrombotic Therapy in XXXX on the Presentation of @entity453 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome', 'acute coronary syndromes']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes mellitus']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary disease']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease-either stable coronary artery disease', 'coronary artery disease']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']

answer: @entity955 :: (MESH:D001281,Disease) :: ['Atrial Fibrillation']


abstract: OBJECTIVE: To evaluate the efficacy of laparoscopic resection of the uterosacral ligaments in @entity1 with @entity601 . DESIGN: Randomized controlled trial. SETTING: Two academic departments. One hundred eighty @entity1 undergoing operative laparoscopy as first-line therapy for stage I to IV symptomatic @entity46 . INTERVENTION(S): Operative laparoscopy including uterosacral ligament resection or conservative surgery alone. MAIN OUTCOME MEASURE(S): Proportion of @entity1 with recurrence of moderate or severe @entity1834 1 year after surgery. RESULT(S): No complications occurred. Among the @entity1 who were evaluable 1 year after operative laparoscopy, 23 of 78 (29%) @entity1 who had uterosacral ligament resection and 21 of 78 (27%) @entity1 who had conservative surgery only reported recurrent @entity1834 . The corresponding numbers of @entity1 at 3 years were 21 of 59 (36%) @entity1 and 18 of 57 (32%) @entity1 , respectively. Time to recurrence was similar in the two groups. @entity158 was substantially reduced, and @entity1 in both groups experienced similar and significant improvements in health-related quality of life, @entity146 profile, and sexual satisfaction. Overall, 68 of 90 (75%) @entity1 in the uterosacral ligament resection group and 67 of 90 (74%) @entity1 in the conservative surgery group were satisfied at 1 year. CONCLUSION(S): Addition of uterosacral ligament resection to conservative laparoscopic surgery for @entity46 did not reduce the medium- or long-term frequency and severity of recurrence of @entity1834 .

title: Laparoscopic uterosacral ligament resection for XXXX associated with @entity46 : results of a randomized, controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity1834 :: ('MESH:D004412', 'Disease') :: ['dysmenorrhea']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity601 :: ('MESH:D009436', 'Disease') :: ['endometriosis and predominantly midline dysmenorrhea']

answer: @entity1834 :: (MESH:D004412,Disease) :: ['dysmenorrhea']


abstract: BACKGROUND: @entity674 ( @entity674 ) may exhibit a fusiform, epithelioid or mixed pattern of growth. Only rare articles report the cytologic and immunohistochemical features of @entity5 . CASE: A 57-year-old @entity1 presented with a @entity5 mass in the small intestine omentum measuring 8 x 7 cm; it was surgically removed. Five years later 2 mesenteric relapses were studied by fine needle aspiration biopsy and later surgically excised. Cytologically the smears contained small clusters of epithelioid and plasmacytoid cells with round nuclei. The presence of nucleoli and occasional nuclear grooves were prominent. Focally the background was myxoid. Histologically the @entity5 showed an epithelioid pattern with moderate pleomorphism and mitoses in 6 of 50 high-power fields. Immunohistochemical study showed positivity for @entity2467 ( @entity2467 ), @entity2277 , smooth muscle actin and caldesmon, and focally for @entity2283 and cytokeratin. CONCLUSION: This case illustrates the difficulty in making a reliable diagnosis of the epithelioid variant of GIST by cytology alone. The immunohistochemical panel (apart from @entity2467 ) should include smooth muscle markers and cytokeratins because they are more likely to be reactive. A complete cytoimmunohistochemical evaluation is mandatory to make an accurate diagnosis.

title: Malignant epithelioid gastrointestinal XXXX : report of a case with cytologic and immunohistochemical studies.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant epithelioid tumors', 'tumor']

entities_list: @entity674 :: ('MESH:D046152', 'Disease') :: ['GISTs', 'Gastrointestinal stromal tumors']

answer: @entity5 :: (MESH:D009369,Disease) :: ['stromal tumors']


abstract: BACKGROUND: @entity8928 ( @entity8928 ) has been known to promote cardiac oxidative stress in models of @entity101 and @entity28 . @entity1502 ( @entity4045 ) is a potent antioxidant. The impact of @entity4045 and @entity8928 on cardiac oxidative status in healthy hearts is unclear. AIM: we aimed to determine the impact of @entity8928 and/or @entity4045 on blood pressure and myocardial oxidative status in normal @entity35 hearts. METHOD: Young adult @entity35 were randomly assigned into four groups; conventional diet (control), @entity8928 , @entity4045 , or simultaneous combination of @entity8928   +   @entity4045 for 10 weeks. Blood pressure, lipids levels, and cardiac levels of oxidants and antioxidants were measured. RESULT: @entity8928 was associated with an increase in @entity412 level and a mild @entity101 (SBP), whereas @entity4045 reduced SBP. Relative to control, no changes were observed in levels of @entity1505 and @entity2041 ( @entity6172 ) system, however, a significant decrease in @entity4466 reactive substances (TBARS) level was observed in all groups with a parallel increase in @entity12609 activities. @entity224 dismutase and @entity12609 activities were increased in the @entity4045 group. Relative to the @entity8928 group, the @entity8928   +   @entity4045 group was associated with a significant increase in the activities of @entity6172 peroxidase and reductase. CONCLUSIONS: The decrease in TBARS levels and the increase in @entity12609 activities suggest that normal hearts adapt compensatory mechanisms to prevent oxidative damage in response to the mild increase in SBP associated with @entity8928 . Use of @entity4045 with @entity8928 further enhanced antioxidant activities probably to balance the potential increase in reactive @entity26 species.

title: An evaluation of the effect of XXXX on blood pressure and myocardial oxidative status following intake of western diet.

entities_list: @entity8928 :: ('MESH:D020241', 'Disease') :: ['Western diet', 'WD']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'increase in systolic blood pressure']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity1502 :: ('MESH:D010431', 'Chemical') :: ['Pentoxifylline']

entities_list: @entity4466 :: ('MESH:C029684', 'Chemical') :: ['thiobarbituric acid']

entities_list: @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague Dawley rats']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['Superoxide']

answer: @entity1502 :: (MESH:D010431,Chemical) :: ['pentoxifylline']


abstract: @entity161 is a common disorder, affecting approximately 1 out of every 100 @entity1 , with a typical onset during adolescence and early adulthood. The personal and societal costs of @entity161 are extremely high. Prevention of @entity161 , would offer substantial benefits to @entity1 , their family members, and the community at large. The prodromal phase of @entity161 has been recognized since the 19th century. At-risk individuals for @entity716 and @entity161 are the subjects who can provide information for intervention prior to development of @entity716 . This approach is currently being investigated. The question remains, however, whether it can be a diagnostic category by itself. The proposal for including the @entity751 is one of the recommendations by the working group on @entity161 and @entity914 for the forthcoming DSM-V. There are differing views in academia regarding this proposal. Prior to becoming fully @entity716 , a consistent literature demonstrates that @entity1 generally had suffered from accelerating attenuated symptoms and distress. It is important that the prodromal phase be accurately recognized in order to accomplish the goal of prevention. We can then purposefully engage in early intervention aiming toward prevention. A recent strong resurgent interest in this area stems largely from two developments: First, the identification of the neurobiological deficit processes associated with the severity and chronicity of @entity161 , and second, the development of reliable criteria for diagnosis. Although the general at-risk construct appears to offer great potential to advance both the treatment and research dealing with @entity716 , it seems premature to many researchers to include the syndrome as an established entity in the text of the new DSM-V. It would be far more appropriate to include this proposed syndrome in the appendix and evaluate the many contemporary issues in future studies. The main issues involved in this discussion are the clinical validity of the syndrome, concern about stigma and unnecessary treatment, and need for responding to @entity1 ' distress in addition to the ethical dilemma. In this review we examine the issue of inclusion of the @entity751 as a diagnosis.

title: "Attenuated @entity716 " as a @entity751 of XXXX , diagnosis in DSM-V: The debate.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people']

entities_list: @entity914 :: ('MESH:D011618', 'Disease') :: ['psychotic disorders']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia', 'Schizophrenia']

entities_list: @entity751 :: ('MESH:D013577', 'Disease') :: ['risk syndrome']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['frank psychosis', 'psychotic', 'psychotic illnesses', 'psychosis']

answer: @entity716 :: (MESH:D011605,Disease) :: ['psychosis']


abstract: OBJECTIVE: To evaluate the diagnostic value of liver @entity82 markers and ultrasonic examination for determining compensated @entity1575 in @entity1 with chronic @entity1956 , and screen applicable non-invasive diagnostic marker for compensated @entity1575 . METHODS: Serum @entity7245 ( @entity7245 ), Type III procollagen (PCIII), laminin (LN) and Type IV collagen ( @entity4609 ) were measured from 350 @entity1 with chronic @entity1956 , who were also detected with liver biopsy and ultrasonography. To determine the cut-off value of every serum liver @entity82 marker for diagnosing compensated @entity1575 , data was analysed with clinical epidemiology methods. Then evaluated and compared all the markers. RESULTS: 85 out of 350 @entity1 were diagnosed as compensated @entity1575 by liver biopsy, and 81 had @entity1575 images by ultrasonic examination. @entity7245 achieved the biggest area under the ROC curve. The cut-off values with best sensitivity and accuracy of @entity7245 , PCIII, LN and @entity4609 were 154.35 microg/L, 198.44 microg/L, 137.58 microg/L and 100.80 microg/L respectively. The related diagnostic sensitivities of @entity7245 , PCIII, LN and @entity4609 were 82.4%, 63.5%, 57.3% and 70.6%, specificities were 79.3%, 54.0%, 56.8%, 68.3%, and accuracies were 80.0%, 56.3%, 56.9%, 68.9%, respectively. Parallel tests could increase the diagnostic sensitivity, but decreased specificity and accuracy accordingly. Compared with other non-invasive diagnostic methods, @entity7245 was the best marker (mu > or =1.814, P<0.05). The level of @entity7245 at 119.17 microg/L was suitable for determining compensated @entity82 , with a 87.1% sensitivity, 67.6% specificity, 72.3% accuracy, 46.25% positive predictive value and 94.7% negative predictive value. CONCLUSION: Among the non-invasive serum diagnostic markers for liver @entity82 and ultrasonic examination for @entity82 image, @entity7245 is the best marker for diagnosing compensated @entity1575 .

title: [Screening and evaluation of non-invasive diagnosis markers for compensated @entity1575 in XXXX with chronic @entity1956 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis', 'cirrhosis']

entities_list: @entity7245 :: ('MESH:D000592', 'Disease') :: ['hyaluronic acid', 'HA']

entities_list: @entity1956 :: ('MESH:D006509', 'Disease') :: ['hepatitis B']

entities_list: @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: The high prevalence and incidence of @entity28 and @entity1277 in @entity10479 adolescent @entity1 are serious health problems. Because of the shared risk factors for @entity28 and @entity1277 , a targeted prevention of both conditions is a priority. OBJECTIVE: We determined whether an adapted interpersonal psychotherapy prevention program is more efficacious for reducing excess @entity1017 and worsening @entity1277 than health education in adolescent @entity1 at high risk of @entity28 and @entity1277 . DESIGN: A parallel-group, randomized controlled trial was conducted between September 2008 and January 2013 in a university-based laboratory and a federal research hospital. The study included 113 adolescent (12-17-y-old) @entity1 deemed at high risk of @entity28 and @entity1277 because of a body mass index (BMI) between the 75th and 97th percentiles and reports of episodes of a loss of control over their eating. @entity1 were randomly assigned to participate in an adapted interpersonal psychotherapy or a health-education group program for 12 weekly 90-min group sessions. Follow-up assessments occurred immediately after group programs and at 6 and 12 mo. RESULTS: Participation in both conditions was associated with decreases in expected BMI gain, age-adjusted BMI metrics, the percentage of fat by using dual-energy X-ray absorptiometry, symptoms of @entity308 and @entity148 , and the frequency of loss-of-control eating over 12 mo of follow-up (Ps < 0.001) with no group difference. In follow-up analyses, interpersonal psychotherapy was more efficacious than health education at reducing objective binge eating at the 12-mo follow-up (P < 0.05). CONCLUSIONS: The intervention with adolescent @entity1 with loss-of-control eating is associated with lower age-adjusted BMI and percentage of adiposity as well as improved mood symptoms over 1 y. Interpersonal psychotherapy further reduced objective binge eating. Additional research is needed to elucidate the mechanisms by which physical and psychological improvements were observed. This trial was registered at clinicaltrials.gov as NCT00680979.

title: Targeted prevention of excess XXXX in high-risk adolescent @entity1 : a randomized controlled trial.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['adult obesity', 'obesity']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity1277 :: ('MESH:D001068', 'Disease') :: ['disordered eating', 'eating disorders']

answer: @entity1017 :: (MESH:D015430,Disease) :: ['weight gain and eating disorders']


abstract: BACKGROUND AND STUDY AIMS: A meta-analysis was conducted to assess the efficacy of transcatheter @entity1416 (TAE) compared with surgery in the management of @entity1 with recurrent @entity360 ( @entity360 ) after failure of endoscopic hemostasis. @entity1 AND METHODS: Publications in English and non-English literatures (OVID, MEDLINE, and EMBASE) and abstracts from major international conferences were searched for studies comparing TAE with surgery for treatment of @entity360 after @entity177 . Outcome measures included rebleeding rate, all-cause mortality rate, and need for additional interventions to secure hemostasis. RESULTS: From 1234 citations, 6 retrospective comparative studies were included that involved 423 @entity1 (TAE, 182, 56% male; surgery, 241, 68% male). TAE @entity1 were older (mean age, TAE 75, surgery, 68). The risk of rebleeding was significantly higher in TAE @entity1 compared with surgically treated @entity1 (relative risk [RR] 1.82, 95% confidence interval [95%CI] 1.23-2.67), with no statistically significant heterogeneity among the included studies (P=0.66, I (2)=0.0%). After sensitivity analysis excluding studies with a large age difference between the two groups, a higher risk of @entity548 remained in the TAE group (RR 2.64, 95%CI] 1.48-4.71). No significant difference in mortality (RR 0.87, 95%CI 0.59-1.29) or requirement for additional interventions (RR 1.67, 95%CI 0.75-3.70) was shown between the two groups. CONCLUSION: A higher rebleeding rate was observed after TAE, suggesting surgery more definitively secured hemostasis, with no significant difference in mortality rate or requirement of additional interventions. The TAE @entity1 were older and in poorer health, thus future randomized studies are needed for accurate comparison of the two modalities.

title: Embolization versus surgery for peptic ulcer XXXX after failed endoscopic hemostasis: a meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1416 :: ('MESH:D020762', 'Disease') :: ['arterial embolization']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['endoscopic hemostasis failure']

entities_list: @entity360 :: ('MESH:D006471', 'Disease') :: ['NVUGIB', 'nonvariceal upper gastrointestinal bleeding']

answer: @entity548 :: (MESH:D006470,Disease) :: ['bleeding']


abstract: INTRODUCTION: @entity5513 ( @entity5513 ) @entity5 size, a significant prognostic indicator, is closely analyzed in @entity1 undergoing observation or treatment. It has historically been reported in terms of linear size; however, volumetric assessments can now be performed routinely. We examine the use of described measurement techniques in large published clinical series to assess their consistency. METHODS: Computerized searches of the MEDLINE database (Pubmed) from 1975 to August 2014 were conducted with the purpose of identifying large series describing the management of VSs. Articles that reported @entity5 size measurements were included if they described greater than 600 @entity1 . RESULTS: 19 studies were found fitting the inclusion criteria, consisting of large retrospective studies with sample sizes ranging from 614 to 2991. A total of 17 studies reported linear measurements, while 2 studies reported volumetric assessments of @entity5 size. Significant variations were found regarding methods for linear measurement. Furthermore, several papers did not provide any details regarding the measurement technique. Inclusion of intracanalicular portions of the @entity5 was highly variable. Volume assessments were performed by segmented volume analysis. CONCLUSIONS: Among the large published series on VSs, significant variation exists regarding the utilized measurement technique to assess size. Volumetric assessments have the greatest clinical utility, sensitivity and accuracy in measuring @entity5 size and growth. Standardization of volume assessments will provide the best method for producing consistent literature findings.

title: Analysis of XXXX size: A literature review on consistency with measurement techniques.

entities_list: @entity5513 :: ('MESH:D009464', 'Disease') :: ['Vestibular schwannoma', 'VS']

answer: @entity5513 :: (MESH:D009464,Disease) :: ['vestibular schwannoma']


abstract: BACKGROUND: The incidence and prognostic impact of late @entity548 complications after transcatheter aortic valve replacement (TAVR) are unknown. OBJECTIVES: The aim of this study was to identify the incidence, predictors, and prognostic impact of major late @entity548 complications (MLBCs) (>= 30 days) after TAVR. METHODS: Clinical and echocardiographic outcomes of @entity1 who underwent TAVR within the randomized cohorts and continued access registries in the PARTNER (Placement of Aortic Transcatheter Valves) trial were analyzed after stratifying by the occurrence of MLBCs. Predictors of MLBCs and their association with 30-day to 1-year mortality were assessed. RESULTS: Among 2,401 @entity1 who underwent TAVR and survived to 30 days, MLBCs occurred in 142 (5.9%) at a median time of 132 days (interquartile range: 71 to 230 days) after the index procedure. @entity344 (n  = 58 [40.8%]), @entity16 (n  = 22 [15.5%]), and traumatic falls (n  = 11 [7.8%]) were identified as the most frequent types of MLBCs. Independent predictors of MLBCs were the presence of low hemoglobin at baseline, @entity955 or @entity5069 at baseline or 30 days, the presence of moderate or severe @entity2478 at 30 days, and greater left ventricular mass at 30 days. MLBCs were identified as a strong independent predictor of mortality between 30 days and 1 year (adjusted hazard ratio: 3.91; 95% confidence interval: 2.67 to 5.71; p  < 0.001). CONCLUSIONS: MLBCs after TAVR were frequent and associated with increased mortality. Better individualized and risk-adjusted antithrombotic therapy after TAVR is urgently needed in this high-risk population. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).

title: Incidence, predictors, and prognostic  impact of late XXXX complications after transcatheter aortic valve replacement.

entities_list: @entity2478 :: ('MESH:D019559', 'Disease') :: ['paravalvular leak']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological complications']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['Gastrointestinal complications']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

answer: @entity548 :: (MESH:D006470,Disease) :: ['bleeding']


abstract: UNASSIGNED: Locally applied @entity171 , such as @entity4381 , have been shown in several studies to inhibit peri-implant bone resorption and recently to enhance peri-implant bone formation. Studies have also demonstrated positive effects of @entity692 (HA) particles on peri-implant bone regeneration and an enhancement of the anti-resorptive effect of @entity171 in the presence of @entity460 . In the present study, both @entity692 nanoparticles (nHA) and @entity4381 were combined to achieve a strong reinforcing effect on peri-implant bone. The nHA- @entity4381 combination was first investigated in vitro with a pre-osteoclastic cell assay (RAW 264.7) and then in vivo in a @entity35 model of @entity170 . The in vitro study confirmed that the inhibitory effect of @entity4381 on @entity19 osteoclast precursor cells was enhanced by loading the drug on nHA. For the in vivo investigation, either @entity4381 -loaded or pure nHA were integrated in hyaluronic acid hydrogel. The gels were injected in screw holes that had been predrilled in @entity35 femoral condyles before the insertion of miniature screws. Micro-CT-based dynamic histomorphometry and histology revealed an unexpected rapid mineralization of the hydrogel in vivo through formation of granules, which served as scaffold for new bone formation. The delivery of @entity4381 -loaded nHA further inhibited a degradation of the mineralized hydrogel as well as a resorption of the peri-implant bone as effectively as unbound @entity4381 . Hyaluronic acid with @entity4381 -loaded nHA, thanks to its dual effect on inducing a rapid mineralization and preventing resorption, is a promising versatile material for bone repair and augmentation. Copyright    2015 John Wiley _ Sons, Ltd.

title: In vitro and in vivo investigation of bisphosphonate-loaded XXXX particles for peri-implant bone augmentation.

entities_list: @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates']

entities_list: @entity170 :: ('MESH:D010024', 'Disease') :: ['postmenopausal osteoporosis']

entities_list: @entity692 :: ('MESH:D017886', 'Chemical') :: ['hydroxyapatite']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronate']

answer: @entity692 :: (MESH:D017886,Chemical) :: ['hydroxyapatite']


abstract: We reviewed the records of 100 consecutive @entity1 with histologically verified @entity977 who underwent transsphenoidal decompression of the optic nerves and chiasm. The @entity1 ' ages ranged from 18 to 80 years, with a median of 52 years. Preoperatively, all @entity1 had objective signs of @entity227 . Postoperatively, visual acuity was normal or improved in 79% of the eyes and the visual fields were normal or improved in 74%. The visual outcome (for both acuity and fields) was better in younger @entity1 and those with a shorter duration of symptoms. @entity1 with lesser degrees of preoperative visual acuity compromise had better postoperative visual acuity outcome. However, the severity of preoperative @entity227 did not seem to predict postoperative field outcome, and even @entity1 with severe preoperative field defects often had striking postoperative improvement. @entity1 who had undergone prior operation were less likely to have either @entity227 after reoperation. @entity86 in visual acuity was noted in only 5 @entity1 (6 eyes). Complications were few. There were 4 instances of @entity5254 , but only 2 @entity1 needed operative repair. There was no instance of permanent @entity2010 , although 17 @entity1 developed transient @entity2010 . In most cases, visual improvement was sustained. The average duration of follow-up was 26 months. Three @entity1 required a subsequent operation to correct @entity227 in the immediate postoperative period, but only 1 @entity1 has undergone late operation for recurrence of @entity5 . There was no operative mortality.

title: Visual recovery after transsphenoidal removal of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual acuity or field defects', 'visual acuity or visual field improvement', 'visual loss', 'visual field defects']

entities_list: @entity5254 :: ('MESH:D002559', 'Disease') :: ['cerebrospinal fluid rhinorrhea']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['Postoperative deterioration']

entities_list: @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenomas']

entities_list: @entity2010 :: ('MESH:D003919', 'Disease') :: ['diabetes insipidus']

answer: @entity977 :: (MESH:D010911,Disease) :: ['pituitary adenomas']


abstract: Pluripotent stem cells are increasingly used for therapeutic models, including transplantation of neural progenitors derived from @entity1 embryonic stem cells (hESC). Recently, long noncoding RNA (lncRNA), including @entity15047 ( @entity15047 ) derived from the @entity11591 - @entity41386 -imprinted locus, were found to be expressed during neural developmental events. Their deregulations are associated with various @entity16 . The @entity11591 - @entity41386 -imprinted locus encodes abundant noncoding RNA (ncRNA) that are regulated by differential methylation on the locus. The aim of our research was to study the correlation between the @entity11591 - @entity41386 -derived ncRNA and the capacity of hESC neural lineage differentiation. We classified hESC into @entity15047 -ON and @entity15047 -OFF based on the expression levels of @entity15047 as well as its downstream microRNA by qRT-PCR. Initial embryoid body (EB) formation was conducted to examine the 3 germ layer's differentiation ability. Complementary DNA microarray was used to analyse the gene expression profiles of hESC. Directed neural lineage differentiation was performed, followed by analysis of neural lineage marker expression levels and neurite formation via qRT-PCR and immunocytochemistry methods to investigate the capacity of neural differentiation in @entity15047 -ON and @entity15047 -OFF hESC. As for statistics, error bars indicate standard error of the mean. Student's t-test was used for calculating P-values, and a P-value of less than 0.05 was considered to be significant. Our results showed that @entity15047 -ON and @entity15047 -OFF hESC differed greatly in @entity11591 - @entity41386 -derived ncRNA expression levels, but had comparable pluripotency gene expression profiles. Genes related to nervous system development and @entity5 were differentially expressed in @entity15047 -OFF hESC, where @entity11591 - @entity41386 -derived ncRNA were repressed compared to @entity15047 -ON ones before differentiation. In neural lineage-like cells derived from @entity15047 -OFF hESC, lower expression levels of neural lineage markers and @entity73 were observed compared to @entity15047 -ON hESC at the same time points after differentiation. We suggest that the expression of @entity11591 - @entity41386 -derived lncRNA, @entity15047 , can be used as a simple and effective screening criterion for identifying @entity15047 -ON hESC with activation of @entity11591 - @entity41386 -imprinted ncRNA as starting materials to benefit neural lineage-associated studies.

title: 346 expression of imprinted noncoding RNA from the @entity11591 - @entity41386 locus in XXXX embryonic stem cells advantages neural lineage differentiation.

entities_list: @entity15047 :: ('55384', 'Gene') :: ['MEG3', 'Maternally Expressed Gene 3']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['neural cancers']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological diseases']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired neurite formation']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: To investigate the predictive value of @entity876 , Ki-67, @entity1722 protein detection in neoadjuvant chemotherapy for @entity420 of @entity11247 (AGEJ). METHODS: Preoperative biopsy specimens and clinical data of 72 @entity1 of locally advanced Siewert II( AGEJ between June 2010 and December 2013 were reviewed. All the @entity1 received SOX scheme neoadjuvant chemotherapy, and were divided into effective group(complete response plus partial response) and ineffective group(stable disease plus @entity74 ). Expressions of above 3 proteins were detected by immunohistochemistry in all the @entity1 before neoadjuvant chemotherapy. The relationship between various proteins and efficacy of chemotherapy was analyzed by univariate and logistic multivariate regression analyses. RESULTS: All the 72 @entity1 successfully completed 2 cycles of SOX neoadjuvant chemotherapy, among them, 5 cases(6.9%) with complete response, 30 cases (41.7%) with partial response, 31 cases(43.1%) with stable disease, 6 cases(8.3%) with @entity74 , including 35 cases in effective group and 37 cases in ineffective group. Compared with ineffective group, the positive expression rate of @entity876 was significantly reduced(25.0% vs. 45.9%, P=0.020), and that of Ki-67 significantly increased (77.1% vs. 43.2%, P=0.003), however, there was no significant difference in the expression rate of @entity1722 between the two groups(P>0.05). Multivariate analysis showed that Ki-67 was the independent predictive factor for the efficacy of neoadjuvant chemotherapy (P=0.015). Spearman rank correlation showed that Ki-67 expression was positively correlated with @entity1722 expression (r=0.259, P=0.028), but @entity876 expression was not correlated with Ki-67 or @entity1722 (r=0.140, 0.042, P=0.240, 0.725, respectively). CONCLUSIONS: SOX neoadjuvant chemotherapy is safe and effective for AGEJ, especially for @entity1 with depressed expression of @entity876 and elevated expression of Ki-67, which both may be used as reference for the prediction of chemotherapy efficacy. There is no correlation between @entity876 and Ki67 proteins, so combined detection may improve the predictive value.

title: [Predictive value of XXXX , Ki-67, @entity1722 protein detection in neoadjuvant chemotherapy for @entity420 of @entity11247 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity11247 :: ('MESH:D008309', 'Disease') :: ['gastroesophageal junction']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity876 :: (7157,Gene) :: ['P53']


abstract: OBJECTIVES: To examine the outcome of surgery for idiopathic @entity5083 (iNPH) and how outcome relates to the preoperative static and pulsatile @entity428 ( @entity428 ). METHODS: An observational cohort study included all @entity1 with iNPH managed at our department during the years 2002-2012 in whom overnight @entity428 monitoring was part of the preoperative work-up. Clinical data were retrieved from a quality registry and @entity428 scores from a pressure database. RESULTS: The study included 472 @entity1 , 316 in the surgery group and 156 in the nonsurgery group. Among those treated surgically, 278 (90%) showed clinical improvement (Responders) whereas 32 (10%) had no improvement (Nonresponders). Among Responders, only about one third reached the best clinical scores; moreover, the difference in clinical score between Responders and Nonresponders declined with time after surgery, particularly after 3-4 years. The surgery was accompanied by acute intracranial @entity1410 in 11 @entity1 (3.5%), of whom 4 (1.3%) died. Survival (age at death) was significantly greater among the Responders than in Nonresponders. Although the static @entity428 was normal in all @entity1 , the @entity428 was significantly greater in Responders than in Non-responders. CONCLUSIONS: The @entity428 was greater in shunt Responders than Nonresponders. Although the clinical improvement declined over time and the majority did not experience complete relief of symptoms, shunt Responders lived significantly longer than Nonresponders. The present observations suggest that the current surgical treatment regimens for iNPH (primarily shunt surgery) address only some aspects of the disease process, in particular the aspect of brain water disturbance.

title: Outcome of Surgery for XXXX : Role of Preoperative Static and Pulsatile Intracranial Pressure.

entities_list: @entity5083 :: ('MESH:D006850', 'Disease') :: ['normal-pressure hydrocephalus']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematomas']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['ICP', 'intracranial pressure', 'pulsatile ICP']

answer: @entity5083 :: (MESH:D006850,Disease) :: ['Idiopathic Normal Pressure Hydrocephalus']


abstract: PURPOSE: To describe the population referred for @entity231 surgery, identify factors that influenced decision to treat, and @entity1 suitable for ophthalmic training. @entity1 AND METHODS: A total of 2,693 consecutive referrals over 6 years were interrogated using Business Objects software on @entity231 electronic @entity1 records. RESULTS: A total of 2,693 @entity1 were referred for @entity231 surgery (group A). Of these @entity1 2,132 (79%) had surgery (group B) and 561 (21%) did not (group C). Age for group B vs group C: 672 (32%) vs 115 (20%)  <=69 years, P<0.001; 803 (38%) vs 225 (40%) 70-79 years, P=0.48; 586 (27%) vs 203 (36%) 80-89 years, P<0.05; 71 (3%) vs 18 (3%) >= 90 years, P=1.0. Visual acuity, group B vs group C: 556 (26%) vs 664 (59%) 6/12 or better; 1,275 (60%) vs 367 (33%) 6/18-6/60; 266 (12%) vs 64 (6%) counting fingers or worse, P<0.05. Medical history for group B vs C: @entity73 : 55 (2.6%) vs 29 (5.2%), P<0.05; @entity65 : 158 (7.4%) vs 60 (10.7%), P<0.05; @entity6 : 372 (17.4%) vs 96 (17.1%), P=0.87; @entity1030 / @entity565 : 382 (17.9%) vs 93 (16.6%), P=0.53; @entity299 : 535 (25.1%) vs 155 (27.6%), P=0.35; @entity101 : 971 (45.5%) vs 263 (46.9%), P=0.73. Ocular history for group B vs C was significant (P<0.05) for age-related @entity1020 255 (12.0%) vs 93 (16.6%), other macular pathology 38 (1.8%) vs 25 (4.5%), corneal pathology 92 (4.3%) vs 36 (6.4%), @entity4457 37 (1.7%) vs 22 (3.9%). Detailed data on presenting complaint, ophthalmic history, and social status is discussed. CONCLUSION: We observed that surgery at a younger age with good levels of visual acuity was a factor in deferring @entity231 surgery. @entity73 , @entity65 , @entity4457 , corneal and macular pathology significantly affected decision not to operate. We estimate that 80% of @entity1 would be suitable for ophthalmic training.

title: XXXX surgery: factors influencing decision to treat and implications for training (south-east Scotland 2008-2014).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'Cognitive impairment']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

entities_list: @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular accident']

entities_list: @entity4457 :: ('MESH:D000550', 'Disease') :: ['amblyopia']

answer: @entity231 :: (MESH:D002386,Disease) :: ['Cataract']


abstract: BACKGROUND: Weight modification after a diagnosis of @entity694 and its impact on outcomes remain unclear. Thus we aimed to examine the association of @entity28 and weight changes from baseline oncology consultation with @entity1349 ( @entity1349 ) and @entity1349 ( @entity1349 ) in @entity1 with @entity5 . METHODS: @entity1 aged  >=  18 years who were diagnosed with @entity5 in British Columbia from 2008 to 2010 and who received adjuvant chemotherapy were included in the study. Cox proportional hazards regression models were fitted to evaluate the impact of different body compositions and degree of weight changes from baseline assessment with outcomes while controlling for potentially confounding covariates, such as age and sex. RESULTS: A total of 539 @entity1 with @entity5 were included: median age was 69 years (range, 26-94 years), 52% were @entity1 , and 53% had Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Those with weight gains of  >=  10% had a median @entity1349 of 37 months compared with 49 months in those with weight gains of  < 10% (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.56-1.59; P  = .82). However, this finding was not significant. In Cox models, @entity1 who exhibited weight losses of  >=  10% experienced significantly inferior @entity1349 (HR, 3.45; 95% CI, 1.44-8.13; P  = .0046) and @entity1349 (HR, 2.63; 95% CI, 1.04-6.67; P  = .041) compared with those who experienced weight losses of <  10%. Weight gains, losses, or changes of equal or less magnitude did not show any significant associations with outcomes (all P > .05). CONCLUSIONS: Weight losses of  >=  10% from baseline evaluation bodes a worse prognosis among @entity1 with @entity5 .

title: Impact of Weight Changes After the Diagnosis of XXXX Cancer on Survival Outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III colon cancer']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'RFS', 'recurrence-free survival', 'overall survival']

answer: @entity694 :: (MESH:D003110,Disease) :: ['Stage III Colon']


abstract: UNASSIGNED: Due to the inability of classical chemotherapeutic agents to exclusively target @entity5 cells, these treatments are associated with severe @entity137 profiles. Thus, long-circulating liposomes have been developed in the past to enhance accumulation in @entity5 tissue by passive targeting. Accordingly, commercially available liposomal formulations of sterically stabilized liposomal @entity632 (Caelyx  , @entity632  , Lipodox  ) are associated with improved off-target profiles. However, these preparations are still not capable to selectively bind to target cells. Thus, in an attempt to further optimize existing treatment schemes immunoliposomes have been established to enable active targeting of @entity5 tissues. Recently, we have provided evidence for therapeutic efficacy of anti- @entity2856 -targeted, surface modified @entity632 loaded liposomes. Our approach involved a technique, which allows specific post-modifications of the liposomal surface by primed antibody-anchor conjugates thereby facilitating personalized approaches of commercially available liposomal drugs. In the current study, post-modification of sterically stabilized liposomal @entity3105 was thoroughly investigated including the influence of different modification techniques ( @entity558 , SPIT, SPIT60), lipid composition ( @entity4203 /Chol, @entity57599 /Chol), and buffers (HBS, SH). As earlier in vivo experiments did not take into account the presence of non-integrated ab-anchor conjugates this was included in the present study. Our experiments provide evidence that post-modification of commercially available liposomal preparations for active targeting is possible. Moreover, lyophilisation represents an applicable method to obtain a storable precursor of surface modifying antibody-anchor conjugates. Thus, these findings open up new approaches in @entity1 individualized targeting of chemotherapeutic therapies.

title: Liposomal XXXX for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo - challenges and prospects.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin', 'Doxil']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

answer: @entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']


abstract: 1. Changes in plasma alpha 1-acid glycoprotein ( @entity14214 ) concentration and immune responses following @entity526 lipopolysaccharide (LPS) injection were studied in broiler @entity1573 . 2. Higher plasma @entity14214 concentrations were observed from 12 to 48 h after a single injection of LPS. 3. The highest concentration of plasma @entity14214 was observed on day 2 followed by a gradual decrease in chicks injected with 150 micrograms/kg body weight of LPS every day for 13 d. 4. Plasma @entity14214 concentration in chicks injected daily with LPS at 900 micrograms/kg body weight for 13 d increased on day 2, and decreased on day 4 to the concentration found before the injection. The concentration increased again on day 10. 5. Changes in plasma interleukin-1 (IL-1) like activity were similar to those in plasma @entity14214 concentration when LPS was injected daily at 900 micrograms/kg body weight for 3 d. 6. Responses of blood mononuclear cell (MNC) proliferation to mitogen or concanavalin A, (Con A), and pokeweed mitogen (PWM) were positively correlated with changes in plasma @entity14214 concentration. 7. The results suggest that plasma @entity14214 concentration could be used as a positive indicator of changes in blood MNC proliferation to a mitogen and in plasma IL-1 like activity.

title: Changes in plasma alpha 1-acid glycoprotein concentration and selected immune response in broiler XXXX injected with @entity526 lipopolysaccharide.

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

answer: @entity1573 :: (9031,Species) :: ['chickens']